

ASIAN INVESTMENT SERIES 2018

13 March 2018 KPMG Hong Kong 15-16 March 2018 KPMG Shanghai

HONG KONG BIOTECH
INVEST & PARTNERING

AUSTRALIA-CHINA BIOTECH
INVEST & PARTNERING



360biolabs

Company Description

360biolabs is a contract research organisation, providing specialist laboratory services for the development of new therapeutics, vaccines and diagnostics in a quality-assured environment. We support pharmacokinetic (PK) and pharmacodynamic (PD) endpoints providing a single laboratory for all your clinical trial requirements (Phase 1-4). Our Quality Management Systems include internationally recognised accreditation (ISO/IEC17025, ISO/IEC15189 and OECD GLP) and our assay validation process and reporting is consistent with FDA and EMEA guidelines.

The 360biolabs executive management team has more than 50 years combined industry experience and we pride ourselves on a highly responsive and proactive approach from quotations to data transfers & reporting.

Pipeline and Developments

NA


What we are looking for:

To engage Chinese biotech or pharmaceuticals companies looking to 1) perform clinical trials in Australia (Phase 1/2a) or 2) use an Australian based laboratory to support international clinical trial sample analysis (Phase 1-4).

Contact:

Name: Angela Luttick
Position: Executive Vice President, Business Development
Company: 360biolabs
Address: 85 Commercial Road, Melbourne Victoria, 3004, Australia
Website: <http://www.360biolabs.com/>
T: +61 3 9282 2285
M: +61 400 641 333
E: a.luttick@360biolabs.com

For more information, please visit www.australiabiotechinvest.com.au

 Follow us for the latest event update #AusBioInv